Carcinoma of the choroid plexus: a pediatric experience.
Carcinoma of the choroid plexus: a pediatric experience.
复制标题
脉络丛癌：儿科经验。
DOI：
--
复制
发表时间：
1993
期刊：
影响因子：
--
通讯作者：
Jean Lemerle
中科院分区：
文献类型：
--
作者：
J. Pierga;C. Kalifa;M. Terrier;Jean‐Louts Habrand;Jean Lemerle
脉络丛癌（CCP）是一种罕见的中枢神经系统肿瘤，多发生于 3 岁以下患者。我们报告了 10 例儿童 CCP 病例。其中男性 5 例，女性 5 例，诊断时年龄 5 至 84 个月（中位 32 个月）。 8 个 CCP 位于侧脑室，2 个位于第四脑室。所有患者均接受初次手术，其中5例完全切除。术后治疗包括4例患者单纯放疗，4例患者单纯化疗，1例患者两者均进行化疗，1例患者未进一步治疗。 6 名患者在 12 至 156 个月（平均 34 个月）的随访中仍处于首次连续完全缓解。这 6 名患者中有 5 名接受了肿瘤的完整手术切除，其中 4 名仅接受了化疗。与文献中的系列比较表明，肿瘤的完全切除是生存的主要预后因素。似乎有必要采取额外的治疗来防止局部复发和中枢神经系统传播。我们认为，应尽可能避免放射治疗，因为它对幼儿有有害作用。由于一些长期幸存者没有接受放射治疗，我们得出的结论是，CCP 可以在术后使用专为患有恶性脑肿瘤的婴儿设计的化疗方案进行治疗。
Carcinoma of the choroid plexus (CCP) is a rare tumor of the central nervous system which occurs more frequently in patients under 3 years of age. We report 10 cases of CCP in children. There were 5 males and 5 females, aged 5 to 84 months at diagnosis (median 32 months). Eight CCP were located in the lateral ventricle and 2 in the fourth ventricle. All patients underwent initial surgery, with complete resection in 5 cases. Postoperative treatment included radiotherapy alone in 4 patients, chemotherapy alone in 4, both in 1 patient, and no further treatment in one patient. Six patients remain in first continuous complete remission with a follow-up of 12 to 156 months (mean 34 months). Five of these six patients had a complete surgical resection of their tumor and 4 of them received chemotherapy alone. A comparison with the series in the literature suggests that total resection of the tumors is the major prognostic factor for survival. Recourse to additional treatments to prevent local relapses and CNS dissemination seems necessary. In our opinion, radiotherapy should be avoided as far as possible because of its deleterious effect in very young children. As some of the long term survivors did not receive radiation treatment, we conclude that CCP can be treated post operatively using chemotherapy protocols designed for infants with malignant brain tumors.